Astria Therapeutics, Inc.

Astria did not give quarterly revenue or EPS figures on this call. The company reported $188.8 million in cash, cash equivalents, and short-term investments as of September 30, 2023, and said it closed a $64 million underwritten offering in October 2023. Management said the post-financing cash balance is expected to support the current operating plan into 2026. On the clinical side, STAR-0215 Phase 1a data in 41 healthy subjects showed concentrations above the 12 micrograms per mil threshold were achieved at about 11 hours after dosing, remained above that threshold for more than 84 days for doses above 100 milligrams, and the half-life was estimated at up to 127 days. Management said there were no serious adverse events or discontinuations due to adverse events, and the most common treatment-emergent adverse events were injection-site reactions. Forward-looking guidance included STAR-0215 proof-of-concept data in HAE patients in Q1 2024, a planned pivotal Phase 3 start in Q1 2025, and STAR-0310 IND submission by year-end 2024 with Phase 1a initiation expected in Q1 2025 and early proof-of-concept in Q3 2025.

Jill Milne framed the quarter as a strong step toward Astria’s goal of building “first choice” therapies for allergic and immunological diseases. She highlighted positive Phase 1a STAR-0215 data, expansion into STAR-0310, and a pipeline strategy centered on clinically validated mechanisms, strong efficacy, low burden, and favorable safety. Her tone was upbeat and focused on execution, with repeated emphasis on upcoming milestones and a desire to accelerate STAR-0215 development where possible.

Noah Clauser said Astria ended September with $188.8 million in cash, cash equivalents, and short-term investments, then raised an additional $64 million in October via an underwritten offering. He said that, on a post-financing basis, the company expects cash to fund the current operating plan into 2026, including STAR-0215 through planned Phase 3 initiation and STAR-0310 through IND submission, Phase 1a, and related milestone payments. He also noted 43.1 million common equivalent shares outstanding, including 36.3 million common shares, 1.6 million pre-funded warrants, and 5.2 million as-converted preferred shares.

Analysts focused on why the STAR-0215 proof-of-concept readout moved up to Q1 2024 and what would constitute a sufficient interim result to proceed to Phase 3. Management said the timeline improved because cohorts 1 and 2 reached target enrollment and the interim analysis trigger is expected earlier than planned; they added that meaningful data would be judged by whether dosing can support both three-month and six-month regimens and by reductions in monthly attack rates or attack-free periods. Questions also centered on Phase 3 design, enrollment risk from using a placebo arm, payer dynamics, awareness-building, and biomarkers; management said Phase 3 is currently expected to be placebo-controlled, likely about six months long, may face some enrollment impact, but could be helped by strong proof-of-concept data, global trial participation, community support, and continued KOL engagement. On biomarkers, management said PK/PD will support the regulatory package but not replace the clinical dataset.